智通财经网·2026-01-23 07:40Core Viewpoint - Zhaoyan New Drug (06127) has seen a stock price increase of over 5%, currently trading at 25.74 HKD, with a transaction volume of 116 million HKD, following the announcement of its annual performance forecast, which indicates a significant expected increase in net profit for 2025 [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 233 million to 349 million RMB for 2025, representing a year-on-year growth of about 214.0% to 371.0% [1] - The increase in net profit is attributed to the rise in market prices of biological assets and the natural growth appreciation of its own assets, contributing positively to the company's performance [1] - The fair value change of biological assets is expected to contribute approximately 452 million to 500 million RMB to net profit [1] Group 2: Market Insights - A senior investment advisor from Yuekai Securities noted that the average consumption of monkeys for a new drug from laboratory to clinical stage is 60, with the dosage for macromolecular drugs potentially doubling [1] - Recent market reports indicate that the price of the core species, the crab-eating macaque, has surged to 120,000 to 130,000 RMB within a month, with some scarce sources reported at 150,000 RMB, reflecting a price increase of over 30% compared to two months ago [1]